Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608889 | 0.84 | KDM4E (0.34) | KDM4EMAPTMAPK1GPBAR1ALDH1A1 | |
| SCHEMBL3604728 | 0.81 | KDM4E (0.39) | POLBGRM2KDM4EMAPTGPBAR1 | |
| SCHEMBL3614091 | 0.75 | MAPT (0.34) | KDM4EMAPTGPBAR1ALDH1A1MEN1 | |
| SCHEMBL3608798 | 0.75 | POLB (0.40) | POLBKDM4EMAPTGPBAR1ALDH1A1 | |
| SCHEMBL3606741 | 0.74 | POLB (0.45) | POLBLMNA | |
| SCHEMBL3611093 | 0.72 | ALDH1A1 (0.35) | POLBKDM4EMAPTGPBAR1ALDH1A1 | |
| SCHEMBL3610663 | 0.71 | ALOX5 (0.32) | KDM4EMAPT | |
| SCHEMBL3614101 | 0.70 | KDM4E (0.35) | KDM4EMAPTGPBAR1HSD17B10TSHR | |
| SCHEMBL3614488 | 0.69 | AR (0.42) | ARSCN9A | |
| SCHEMBL3611438 | 0.69 | KDM4E (0.35) | KDM4EMAPTGPBAR1SMN1; SMN2SHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | POLB 3604/4885GRM2 3072/4885KDM4E 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.